Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
about
Radiogenomic mapping of edema/cellular invasion MRI-phenotypes in glioblastoma multiformePericytes promote endothelial cell survival through induction of autocrine VEGF-A signaling and Bcl-w expressionThe Emerging Regulation of VEGFR-2 in Triple-Negative Breast CancerMicroRNAs and Potential Targets in Osteosarcoma: ReviewTargeting angiogenesis in gynecologic cancersNovel hepatocellular carcinoma molecules with prognostic and therapeutic potentialsPG545, a heparan sulfate mimetic, reduces heparanase expression in vivo, blocks spontaneous metastases and enhances overall survival in the 4T1 breast carcinoma modelA phase I, open-label study of trebananib combined with sorafenib or sunitinib in patients with advanced renal cell carcinomaVEGFR1 and VEGFR2 involvement in extracellular galectin-1- and galectin-3-induced angiogenesis.Increased efficacy of breast cancer chemotherapy in thrombocytopenic miceSunitinib as salvage treatment including potent anti-tumor activity in carcinomatous ulcers for patients with multidrug-resistant metastatic breast cancerPhase I study of pazopanib plus TH-302 in advanced solid tumors.Noninvasive assessment of tumor VEGF receptors in response to treatment with pazopanib: a molecular imaging studyThe role of targeted agents in the adjuvant treatment of colon cancer: a meta-analysis of randomized phase III studies and reviewAnti-angiogenic therapy for cancer: current progress, unresolved questions and future directions.A Review of the Structure, Preparation, and Application of NLCs, PNPs, and PLNs.Prognostic significance of AMPK activation in advanced stage colorectal cancer treated with chemotherapy plus bevacizumab.Targeted nanoparticles that deliver a sustained, specific release of Paclitaxel to irradiated tumors.Focal adhesion kinase: an alternative focus for anti-angiogenesis therapy in ovarian cancer.Intrinsic resistance to tyrosine kinase inhibitors is associated with poor clinical outcome in metastatic renal cell carcinoma.The combination of HTATIP2 expression and microvessel density predicts converse survival of hepatocellular carcinoma with or without sorafenibAngiopoietins promote ovarian cancer progression by establishing a procancer microenvironment.Limitations of the dorsal skinfold window chamber model in evaluating anti-angiogenic therapy during early phase of angiogenesisGemcitabine plus bevacizumab compared with gemcitabine plus placebo in patients with advanced pancreatic cancer: phase III trial of the Cancer and Leukemia Group B (CALGB 80303).Experimental treatment of oestrogen receptor (ER) positive breast cancer with tamoxifen and brivanib alaninate, a VEGFR-2/FGFR-1 kinase inhibitor: a potential clinical application of angiogenesis inhibitorsPotential relevance of bell-shaped and u-shaped dose-responses for the therapeutic targeting of angiogenesis in cancerDelta-like ligand 4: A predictor of poor prognosis in clear cell renal cell carcinomaPharmacodynamic change in plasma angiogenic proteins: a dose-escalation phase 1 study of the multi-kinase inhibitor lenvatinib.Tumors that acquire resistance to low-dose metronomic cyclophosphamide retain sensitivity to maximum tolerated dose cyclophosphamide.Chronic inhibition of tumor cell-derived VEGF enhances the malignant phenotype of colorectal cancer cells.Overexpression of tumor vascular endothelial growth factor A may portend an increased likelihood of progression in a phase II trial of bevacizumab and erlotinib in resistant ovarian cancerInhibition of tumor-associated αvβ3 integrin regulates the angiogenic switch by enhancing expression of IGFBP-4 leading to reduced melanoma growth and angiogenesis in vivo.Drug waste minimization as an effective strategy of cost-containment in oncology.Systems pharmacology approaches for optimization of antiangiogenic therapies: challenges and opportunities.Inhibition of cyclo-oxygenase 2 reduces tumor metastasis and inflammatory signaling during blockade of vascular endothelial growth factor.Biomarkers in tumor angiogenesis and anti-angiogenic therapy.Sustained systemic response paralleled with ovarian metastasis progression by sunitinib in metastatic renal cell carcinoma: Is this an anti-angiogenic potentiation of cancer?Antiangiogenic therapy: impact on invasion, disease progression, and metastasis.Carbonic anhydrase IX promotes tumor growth and necrosis in vivo and inhibition enhances anti-VEGF therapyA streamlined search technology for identification of synergistic drug combinations.
P2860
Q21135142-0570C7C4-0734-41E8-BA88-CC74AFAF5073Q24595357-EF73F041-7696-4652-B242-99C63DF969C0Q26779248-201463C9-5B88-4AE0-AF6F-3BF842C68868Q26784033-D8149C8E-B379-4AD3-913A-BA48B9F90A70Q26824766-30963161-88EA-4EBD-B0D2-A53009301489Q26824909-DBCC3468-F1D1-409E-A3EB-2347113768A2Q27327191-FA1BDFBC-0273-4F8C-978B-755BD3640FDCQ28304566-A7D3B8D3-BC2E-4B29-8B67-CC8BD2125E3BQ31121321-5D41003C-1D54-4894-A877-9F4CC31239C1Q33393552-460C589B-0866-4B33-B5CD-1C46265C04DDQ33434465-CFC5BF7D-8DAE-4A6C-814B-C458F3189D56Q33439635-52456433-8A61-4250-896B-E565F6D2219EQ33655366-EEC280D7-1C99-4B69-9DF7-C39E7ACF9358Q33761655-A35857BA-0E67-4AD9-80EB-FEC536725E28Q33770680-41D11839-DEED-4AC5-8815-C17F6C9DEB6AQ33837845-8B91E548-81C7-420B-B198-519E83CAEC80Q33877467-B08D92FB-C2AE-4A9B-A245-2F687D613E8DQ33891952-A18B08AD-7139-4D2E-8B0A-539127ADF5C0Q33911213-34A0FC42-8BF9-479A-9BB2-B0CE2705644EQ33960788-E92B14F3-BDB9-4661-BF7D-CDDA0172141EQ33977116-9E7FBC89-6E0D-4687-99BD-16617B853881Q33978086-7874AEAF-ABD9-4349-9AA2-A5D4ADD22CB6Q34008504-807293E1-6C79-42A2-9302-F15721112049Q34049260-1F3BBCC0-7062-4ACC-B840-DB6075FA36B6Q34082909-BCCB61D8-00B0-4F07-BADA-64D0DC48A290Q34128953-0CEFDFF0-E7B3-43F3-815B-B4CCD8E7D8CDQ34427294-35D31938-A330-4AE2-8D7A-932B9149F5D4Q34468729-C55CFDE6-B91E-4AB2-A58F-84D003BA48E2Q34497992-2EA033DE-15B9-4347-AF98-92E939E326C5Q34708917-0C4E11C0-D322-419A-8256-36605109662CQ34781970-59DB2A6C-9EA4-40EA-8ACE-1847704200F5Q34799434-73CAF319-AD37-473E-A442-4E1E770EFC0DQ35089146-284296EE-34AA-49AF-8990-A8E124B08CEDQ35104052-AA7DC57D-1C0F-4895-9B9D-C78AFA7584E9Q35413008-BFB50589-0DA7-4165-B5E6-359E68EC3333Q35536088-8983AE74-9C1D-4B66-BC9A-96AE062BA769Q35898650-D08EB5A2-EDE2-433F-920C-5BDDB4DD876AQ35966757-82FE722B-D94C-44BB-A0F2-38C13E259731Q36007805-ED159D87-4256-4DA9-A372-81C19BF3846BQ36101810-454DA729-564B-4534-8904-5F4C7710C748
P2860
Tumor and host-mediated pathways of resistance and disease progression in response to antiangiogenic therapy.
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 11 August 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Tumor and host-mediated pathwa ...... nse to antiangiogenic therapy.
@en
Tumor and host-mediated pathwa ...... nse to antiangiogenic therapy.
@nl
type
label
Tumor and host-mediated pathwa ...... nse to antiangiogenic therapy.
@en
Tumor and host-mediated pathwa ...... nse to antiangiogenic therapy.
@nl
prefLabel
Tumor and host-mediated pathwa ...... nse to antiangiogenic therapy.
@en
Tumor and host-mediated pathwa ...... nse to antiangiogenic therapy.
@nl
P2860
P1476
Tumor and host-mediated pathwa ...... onse to antiangiogenic therapy
@en
P2093
Christina R Lee
Robert S Kerbel
P2860
P304
P356
10.1158/1078-0432.CCR-09-0095
P407
P50
P577
2009-08-11T00:00:00Z